The genome sequence of Mycobacterium leprae revealed a single open reading frame, ML2088 (CYP164A1), encoding a putative full-length cytochrome P450 monooxygenase and 12 pseudogenes. We have identified a homolog of ML2088 in Mycobacterium smegmatis and report here the cloning, expression, purification, and azole-binding characteristics of this cytochrome P450 (CYP164A2). CYP164A2 is 1,245 bp long and encodes a protein of 414 amino acids and molecular mass of 45 kDa. CYP164A2 has 60% identity with Mycobacterium leprae CYP161A1 and 66 to 69% identity with eight other mycobacterial CYP164A1 homologs, with three identified highly conserved motifs. Recombinant CYP164A2 has the typical spectral characteristics of a cytochrome P450 monooxygenase, predominantly in the ferric low-spin state. Unusually, the spin state was readily modulated by increasing ionic strength at pH 7.5, with 50% high-spin occupancy achieved with 0.14 M NaCl. CYP164A2 bound clotrimazole, econazole, and miconazole strongly (K d , 1.2 to 2.5 M); however, strong binding with itraconazole, ketoconazole, and voriconazole was only observed in the presence of 0.5 M NaCl. Fluconazole did not bind to CYP164A2 at pH 7.5 and no discernible type II binding spectrum was observed.Leprosy has afflicted humanity through the ages and remains today a serious and disfiguring condition in communities throughout the developing world. Immunization (18) and multidrug treatment programs have been effective in reducing morbidity and mortality due to lepromatous leprosy, but the incidence of new infections, at 680,000 per annum (36), remains high. Genome sequencing projects have been completed for several mycobacterial species, including both Mycobacterium leprae, the etiologic agent of leprosy, and Mycobacterium tuberculosis. A common objective of these schemes is to identify potential targets for the development of novel antimycobacterial compounds. Unusually for bacteria, the actinomycetes such as mycobacteria and streptomycetes contain substantial numbers of genes encoding cytochromes P450 (CYPs) or P450 pseudogenes (6, 23). These enzymes carry out a wide range of monooxygenation reactions involved in biocatalysis, secondary metabolism, and detoxification. CYPs are ubiquitous throughout the eukaryotes but are relatively uncommon in prokaryotes, with most prokaryotes containing no CYP genes. The unexpected discovery in M. tuberculosis of an ortholog of CYP51 (3), the sterol 14␣-demethylase of eukaryotes (19), proved a major catalyst for investigations into the CYP complements (CYPomes) of mycobacteria, as CYP51 is the target for azole antifungal drugs that have been shown to possess antimycobacterial properties (1,5,15,35).Most azole antifungal compounds show selective targeting of CYP51, having an 8-to 128-fold-higher affinity for fungal CYP51s relative to the orthologous enzyme present in the host (29). These compounds act by inhibiting the fungal sterol biosynthesis pathway, which does not exist in mycobacteria. The abundance of P450 proteins in mycobacterial species...